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Background: The use of malaria-specific quantitative real-time PCR (qPCR) is increasing due to its high sensitivity,
speciation and quantification of malaria parasites. However, due to the lack of consensus or standardized methods
in performing qPCR, it is difficult to evaluate and/or compare the quality of work reported by different authors for a
cross-study and/or cross-platform assay analysis.
Methods: The performances of seven published qPCR assays that detect Plasmodium spp or Plasmodium falciparum
were compared using standard DNA and samples from a clinical trial. Amplification and qPCR measurements
were performed using the Applied Biosystems 7500 Fast Real-Time PCR System. All the analyses were
automatically established using the default settings. For the TaqMan probe format, the assays were
performed in the background of QuantiFast Probe Master Mix whereas in SYBR Green format, the assays
were performed in the background of QuantiFast SYBR Green Master Mix and QuantiTect SYBR Green Master
Mix background.
Results: Assays with high PCR efficiencies outperformed those with low efficiencies in all categories
including sensitivity, precision and consistency regardless of the assay format and background. With the
exception of one assay, all assays evaluated showed lower sensitivity compared to what have been
published. When samples from a malaria challenge study were analysed, the qPCR assay with the overall
best performance detected parasites in subjects earliest and with most consistency.
Conclusion: The data demonstrate the need for increased consensus and guidelines that will encourage
better experimental practices, allowing more consistent and unambiguous interpretation of qPCR results.Background
The gold standard method for malaria diagnosis is mi-
croscopy [1,2]. However, numerous challenges associated
with performing quality microscopy may lead to varia-
tions in assay sensitivity and specificity [3,4] affecting pa-
tient diagnostic outcome and/or clinical trial results [5].
Microscopy is highly operator-dependent and proficiency
testing is required to achieve reproducible, high-quality
data [6]. Molecular assays that detect Plasmodium-specific
nucleic acid sequences are increasingly being implemented
in order to overcome some of the limitations associated* Correspondence: edwin.kamau@us.army.mil
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distribution, and reproduction in any mediumwith microscopy. These assays are several orders of magni-
tude more sensitive than microscopy or antigen detection
tests [7,8]. Malaria-specific applications of quantitative real-
time PCR (qPCR) have allowed for identification, speciation
and quantification of malaria parasites [7-14]. Notably,
qPCR is increasingly being used to analyse pre-patent
parasitaemia in controlled human malaria infection (CHMI)
trials as well as evaluation of low parasitaemia in field
studies [15-19]. PCR can also be used as a tool for iden-
tification of asymptomatic carriers [20].
Most of the qPCR assays that have been described
for detection of Plasmodium target the multicopy 18S
ribosomal RNA (rRNA) genes [21]. Other targets suchtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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been described [13,21]. These assays are designed as
monoplex where they amplify a single target or as multi-
plex, where they amplify two targets or more. When used
as a monoplex assay, the reported detection limit ranges
from about 0.002 to 30 parasites/μL [14,21] whereas
as a multiplex, the detection limit ranges from 0.2 to
5 parasites/μL [7,8,14,21]. Hermsen et al. [9] and Lee
et al. [10] described some of the early monoplex qPCR
assays for detection of Plasmodium spp with a detec-
tion limit of 0.02 parasites/μL and 0.1 parasites/μL re-
spectively. Both of these studies targeted the rRNA genes.
Recently, Farrugia et al. [13] described a monoplex
assay that targets cytochrome b gene (ctyb) with a de-
tection limit of 0.05 parasites/μL. Although these and
other studies follow similar study methods, differences
in space and time, reagents, standards used for quanti-
fication, dilution ranges, instruments or platforms,
assay analysis methods, data interpretations, and much
more, contribute to differences in the reported detection
limits. Due to lack of consensus or standardized methods
in performing qPCR, it is difficult to evaluate and/or com-
pare the quality of work reported by different authors
for a cross-study and/or cross-platform assay analysis.
This also impedes the ability to reproduce reported
assays.
The minimum information for publication of quanti-
tative real-time PCR experiments (MIQE) guidelines
were published recently [22]. They address the reli-
ability of qPCR results to help ensure the integrity of
the scientific literature, promote consistency between
laboratories, and increase experimental transparency.
The use of malaria qPCR as a confirmatory clinical
endpoint assay in field research is increasing exponen-
tially as reflected in the large number of publications
reporting qPCR data. In addition, there have been dis-
cussions of molecular assays replacing microscopy as
the preferred diagnostic tool for malaria, especially in
reference laboratories and in CHMI trials. The lack of
consensus on how to best perform qPCR has led to
serious difficulty in establishing PCR as an independ-
ent yardstick [22] and currently, there is not an FDA
approved qPCR assay for detection of malaria. Use of
MIQE and other guidelines set-forth will ensure qPCR
relevance, accuracy, correct interpretation, reliability,
and reproducibility. Towards this effort, it is import-
ant to obtain harmonized data from some of currently
widely used malaria qPCR assays as an important step
towards assay standardization.
In this study, the performance of several published
qPCR assays using the WHO international standard
for Plasmodium falciparum DNA nucleic acid ampli-
fication technology assay as a calibration reference
reagent were compared. The experimental conditions,assay analysis methods and data interpretation were
uniformly performed for all qPCR assays assessed.
Methods
Plasmodium falciparum reference reagent
The WHO International Standard for Plasmodium falcip-
arum DNA was used to analyse the efficiency, sensitivity
and specificity of published assay targets for Plasmodium
spp. and P. falciparum. The reference reagent was obtained
from the National Institute for Biological Standards and
Control (NIBSC; Hertfordshire, UK). This standard con-
sists of a freeze-dried preparation of whole blood collected
from a patient infected with P. falciparum by exchange
transfusion. Following NIBSC recommendations, the
lyophilized material was suspended in 500 μL of sterile,
nuclease free water to a final concentration of 1 ×
10,993 IU/mL, which corresponds to a parasitaemia of
9.79 parasites/100 red blood cells (RBCs) [13]. The para-
site density of the WHO International Standard for
P. falciparum DNA after the reconstitution was esti-
mated to be 469,920 parasites/μL, based on the average
RBC count of 4.8 × 106 RBC/μL. Unless otherwise indi-
cated, fresh uninfected whole blood was used as a diluent
to prepare serial dilutions. DNA was extracted using EZ1
automated purification system (Qiagen, CA, USA) using
the EZ1 DNA blood kit (Qiagen, CA, USA) following
the manufacturer’s recommendation. For the purposes
of establishing the limit of detection (LoD), DNA was
serially diluted five-fold for the first four dilution points
followed by two-fold dilutions over five-log range. The
lowest concentration of DNA that tested positive in all
the replicates was set as the LoD.
Primers and probes
Seven sets of primers and probes for the detection of
Plasmodium spp. and P. falciparum were selected from
published work. Table 1 shows the primers and probes
sequences selected for this project as published. They
were obtained either from Life Technologies (Carlsbad,
CA, USA) or Integrated DNA Technologies (IDT-DNA,
Coralville, IA, USA). For purposes of simplicity and
uniformity, all probes for all the assays were labelled
with 6-carboxy-fluorescein (FAM) as a reporter and 6-
carboxy-tetramethylrhodamine (TAMRA) as a quencher.
qPCR assays and experimental design
Amplification and qPCR measurements were performed
using the Applied Biosystems 7500 Fast Real-Time PCR
System, with version 2.0.6 software. All the analyses, in-
cluding setting of the threshold and the quantification
cycle (Cq) values, were automatically established using
the default settings. Experiments were performed in 96-
well plates. For the TaqMan probe format, the assays
were performed in the background of QuantiFast Probe
Table 1 Published primers and probes used in analysis
Assay
name
Primer and Probe sets as published
in 5—3 orientation
Ref #
PLU3 F: GCTCTTTCTTGATTTCTTGGATG [14]
R: AGCAGGTTAAGATCTCGTTCG
P: ATGGCCGTTTTTAGTTCGTG
MACH F: ACATGGCTATGACGGGTAACG [10]
R: TGCCTTCCTTAGATGTGGTAGCTA
P: TCAGGCTCCCTCTCCGGAATCGA
CYTB F: TACTAACTTGTTATCCTCTATTCCAGTAGC [13]
R: CCTTTAACATCAAGACTTAATAGATTTGGA
P: G + TGC + TAC + CAT + GTA + AAT + GTAA
WHO F: CAGATGTCAGAGGTCAAATTCTAAGATT [12]
R: TCCCTTAACTTTCGTTCTTGATTAATG
P: CTGGAGACGGACTACTGCGAAAGCATTTG
FAL F: CTTTTGAGAGGTTTTGTTACTTTGAGTAA [7]
R: TATTCCATGCTGTAGTATTCAAACACAA
P: TGTTCATAACAGACGGGTAGTCATGATTGAGTTCA
PLASMO F: GTTAAGGGAGTGAAGACGATCAGA [11]
R: AACCCAAAGACTTTGATTTCTCATAA
P: ACCGTCGTAATCTTAACCATAAACTATGCCGACTAG
TURBO F: GTAATTGGAATGATAGGAATTTACAAGGT [9]
R: TCAACTACGAACGTTTTAACTGCAAC
P: TGCCAGCAGCCGCGGTAATTC
Primers and probes sequences as published. Forward and reverse primers are
shown as F and R. All probes shown as P were labelled with 6-carboxy
-fluorescein (FAM) as a reporter and 6-carboxy-tetramethylrhodamine (TAMRA)
as a quencher to maintain uniformity. The last column shows the reference
where primers and probe for each assay were obtained.
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were performed in the background of QuantiFast SYBR
Green Master Mix and QuantiTect SYBR Green Master
Mix background (Qiagen, CA, USA). The following thermal
profiles described below are for each master mixes used:
QuantiFast Probe TaqMan:
Stage 1(Holding Stage): 95°C for 5 min
Stage 2 (Cycling Stage): 95°C for 10 sec, 60°C for 30 sec}
45 Cycles
QuantiFast SYBR Green:
Stage 1 (Holding Stage): 95°C for 5 min
Stage 2 (Cycling Stage): 95°C for 10 sec, 60°C for 30 sec}
45 Cycles
Stage 3 (Melt Curve Stage): 95°C for 15 sec, 68°C for
60 sec, 80°C for 15 sec, 60°C for 15 sec
QuantiTect SYBR Green:
Stage 1 (Holding Stage): 95°C for 15 min
Stage 2 (Cycling Stage): 95°C for 15 sec, 60°C for 30 sec,
72°C for 30 sec } 45 CyclesStage 3 (Melt Curve Stage): 95°C for 15 sec, 60°C for
60 sec, 72°C for 30 sec, 60°C for 15 sec
For each set of primers and probes described in Table 1
(QuantiFast Probe TaqMan), reaction mix consisting of
11 μL of 2× QuantiFast Master Mix, 1 μL of each10 uM
(0.4 μM) forward and reverse primer, and 1 μL of 5 μM
probe (0.2 μM) and 6 μL of nuclease-free water was made
to a total volume of 20 μL. From this, 5 μL of the mix to
1 μL template was used per reaction. For QuantiFast
SYBR Green Master Mix or QuantiTect SYBR Green
Master Mix, 10 μL of 2× master mix, 1 μL of each 10 μM
(0.4 μM) forward and reverse primer and 8 μL of
nuclease-free water was made to a total volume of 20 μL.
From this, 9 μL of the mix to 1 μL template was used
per reaction as recommended by the manufacturer.
Good laboratory techniques and quality controls were
strictly adhered. Each assay was run with proper con-
trols in place including no template control, endogen-
ous control and positive controls.
Summary of published assays analysed in this study
1. Kamau et al [14], PLU3: Published LoD 0.0512
parasites/μL, 1 μL of DNA in 10 μL total reaction
volume in 1X QuantiTect Probe RT-PCR Master
Mix (Qiagen). Efficiency not reported. Performed in
ABI7500 platform.
2. Lee et al [10], MACH: Published LoD 0.1 parasites/μL,
5 μL of DNA in 25 μL total reaction volume in
1X TaqMan universal PCR master mix (Applied
Biosystems, CA, USA). Efficiency not reported.
Performed in iCycler (Bio-rad) platform.
3. Farrugia et al [13], CYTB: Published LoD
0.05 parasites/μL, 5 μL of DNA in 20 μL total
reaction volume in 1X Probe Master (Roche
Molecular Biochemicals). Efficiency reported at
94.5%. Performed in a LightCycler 480
instrument.
4. Padley et al [7], WHO: Published LoD 16.2
parasites/μL. The amount of DNA used and reaction
total reaction volume not provided however, reports
amplification reactions were performed using the
Light-Cycler FastStart DNA Master Hybprobe kit
(Roche Applied Science, Mannheim, Germany).
Efficiency not reported. Performed in a LightCycler
2.0 instrument.
5. Perandin et al [12], FAL: Published LoD 0.7
parasites/μL, 5 μL of DNA in 50 μL total reaction
volume in 1X TaqMan universal PCR master mix
(Applied Biosystems). Efficiency not reported.
Performed in ABI 7700 platform.
6. Rougemont et al [11], PLASMO: LoD and Efficiency
not published. 5 μL of DNA in 25 μL total reaction
Figure 1 Comparative evaluation of PCR limit of detection from
published malaria PCR assays. Data showing TaqMan probe
assays performed in the background of QuantiFast Master Mix.
Assays were performed in triplicate. Only Cq values of 40 and below
were considered and only two out of three values were required to
call the results a positive. LoD was established which contained the
lowest parasite concentration expressed as parasites/mL.
Alemayehu et al. Malaria Journal 2013, 12:277 Page 4 of 8
http://www.malariajournal.com/content/12/1/277volume in 1X TaqMan universal PCR master mix
(Applied Biosystems). Performed in ABI 7700 platform.
7. Hermsen et al [18],TURBO: Published LoD 0.02
parasites/μL, 5 μL of DNA in 25 μL total reaction
volume of 25 μL of buffer containing 20 mM Tris-HCl,
100 mM KCl, 3 mM MgCl2, 0.02% gelatin, and
400 μM deoxynucleoside triphosphates
(Microsynth, Balgach, Switzerland). Efficiency not
reported. Performed in a GeneAMP PCR system
9700 (Applied Biosystem).
Analysis of samples obtained from a challenge study
To further compare the assays described here, samples
obtained from five subjects participating in an experi-
mental P. falciparum infection study were analysed in
triplicate using each of the seven assays being tested.
Samples used for analysis were from positive control
challenge subjects who did not receive any investiga-
tional product or licensed anti-malarial medication prior
to challenge by the bite of infected mosquitoes. Samples
were collected in EDTA blood and stored in -20°C im-
mediately until needed. DNA was extracted from the
whole blood using EZ1 automated purification system
(Qiagen, CA, USA) with the EZ1 DNA blood kit (Qiagen,
CA, USA) following the manufacturer’s recommendation.
The study protocol for the clinical trial was reviewed
and approved by the Human Use Review Committee of
the Walter Reed Army Institute of Research (WRAIR)
and by the Human Subjects Research and Review Board
of the Surgeon General of the US Army at Fort Detrick,
Maryland. The study was conducted in collaboration with
US Agency for International Development (USAID), In-
fectious Disease Research Institute. Participants were
provided written, informed consent before screening and
enrolment and had to pass an assessment of under-
standing. The results of the clinical trial study will be
reported elsewhere.
Results
Comparison of PCR assays sensitivities
The fluorescence emission of any molecule is dependent
on environmental factors including the pH of the solu-
tion, salt concentration and much more. To obtain more
accurate and representative performance of all the assays
tested, assays were performed using TaqMan probe and
SYBR Green formats. For the TaqMan probe format, the
assays were performed in the background of QuantiFast
Master Mix whereas in SYBR Green format, the assays
were performed in the background of QuantiFast SYBR
Green Master Mix and QuantiTect Sybr green Master
Mix. All assays were performed in triplicate and the LoD
was established as the highest Cq value where the lowest
parasite concentration was detected, expressed as para-
sites/mL. Only Cq values 40 and below were consideredand only two out of three assays were required to call
the results a positive. It is important to note that at
very low copy numbers, the normal distribution of the
template in the sample is not expected. Instead, Poisson
distribution is followed where only a certain percentage
of copy number of the template is detected which is
likely to vary each time resulting in a larger standard
deviation (SD). For the TaqMan probe format, the
PLU3 and MACH assays were the most sensitive with
LoD of 313 parasites/mL whereas the CTYB and FAL
were the least sensitive with LoD of 2,500 parasites/mL
(Figure 1). The sensitivities of these assays were previously
reported as follows: PLU3 at 50 parasites/mL, MACH
at 100 parasites/mL, CTYB at 50 parasites/mL, WHO
at 16,200 parasites/mL, FAL at 700 parasites/mL, and
TURBO at 20 parasites/mL. The sensitivity of PLASMO
assay was not reported.
Comparison of the dynamic ranges and efficiencies of
PCR assays
Robust and precise qPCR assays are usually correlated
with high PCR efficiency [12]. To evaluate PCR efficiency,
each assay was performed in triplicates, with 5-log range
in five-fold decrements of the template. A slope of -3.3 ±
10% reflects an efficiency of 100% ± 10%. PCR efficiency is
highly dependent on the primers used. The presence of
primer dimers may result in a lower PCR efficiency in a
probe-based assay and may generate false positives in
SYBR Green based assays. In TaqMan probe assay format,
the PLU3 assay had the highest efficiency at 100.4%
whereas FAL had the lowest efficiency at 74.95% (Table 2).
Efficiency for CTYB assay was previously reported as
94.5% [13] whereas in this study, efficiency of 88.2%
was obtained. When the assays were run in SYBR Green
format in the background of QuantiTect SYBR Green
Master Mix, the PLU3 assay performed the best whereas
Table 2 TaqMan probe assay performance
Assay Slope Y-Inter R2 % Eff
PLU3 −3.312 37.145 1 100.412
MACH −3.576 38.969 0.999 90.399
CYTB −3.643 37.54 0.999 88.154
WHO −3.386 38.74 0.998 97.394
FAL −4.116 43.601 0.998 74.954
PLASMO −3.643 36.686 0.998 88.135
TURBO −3.685 39.55 0.998 86.788
Table 4 SD as a measure of precision of assays tested
Assay SD SD SD
Lowest Cq values Highest Cq values LoD Cq values
PLU3 0.044 0.249 0.000
MACH 0.062 0.338 0.142
CYTB 0.113 0.454 1.082
WHO 0.134 0.561 0.943
FAL 0.294 0.996 1.113
PLASMO 0.069 0.561 0.663
TURBO 0.096 0.509 0.200
SD is a measure of precision of each qPCR assay at different parasite
concentrations. Lower values represent higher precision.
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(data not shown). Interestingly, in SYBR Green format,
all assays performed better in QuantiFast SYBR Green
Master Mix than they did in QuantiTect SYBR Green
Master Mix. The PLU3 assay performed with the highest
efficiency in SYBR Green QuantiFast Master Mix at 95.4%
whereas FAL had the lowest efficiency at 40.1% (Table 3).Comparison of R2 values and precision of PCR assays
Correlation co-efficient R2 value is a statistical term that
indicates how predictive one value is of another. It is
also a critical value for evaluating PCR efficiency. The
value of Y (Cq) can be used to accurately predict the
value of X when the R2 is 1. An R2 value of 0.99 provides
good confidence in correlating two values. Using the
QuantiFast probe TaqMan assay format, the R2 values of
all the assays were >0.99 (Table 2). There are numerous
causes for variations in qPCR results, including temperature
differences (temperature affects annealing and/or denatur-
ation), pipetting errors, stochastic variation, etc. SD is a
measure of precision that typically varies in qPCR with con-
centration and with decreasing copy number. To compare
the precision of the assays tested, the SD of Cq values in
two different dilutions containing 4,699 parasites/μL [high]
and 4.7 parasites/μL [low] of the TaqMan assays were
evaluated. In addition, SD at LoD was determined. The
PLU3 assay had the smallest SD at all the parasite con-
centrations tested, which indicated superior performance
whereas FAL had the poorest performance (Table 4).Table 3 SYBR Green QuantiFast assay performance
Assay Slope Y-Inter R2 % Eff
PLU3 −3.438 35.132 0.999 95.389
MACH −3.627 37.421 0.998 88.683
CYTB −3.605 36.122 0.997 89.419
WHO −3.585 38.815 0.999 90.095
FAL −6.834 57.967 0.998 40.067
PLASMO −4.07 40.183 0.998 76.088
TURBO −4.092 42.658 0.998 75.551Analysis of samples from clinical trial study
The seven assays being tested were further evaluated
using clinical samples from five unvaccinated positive
control subjects as described in methods section. Sam-
ples were analysed in triplicate using the TaqMan probe
assay format, performed in the background of QuantiFast
Probe Master Mix. Microscopy was used as the reference
method for the detection of parasites and initiation of
treatment whereas qPCR was used as an exploratory
method. Samples were considered microscopy positive
when a minimum of two unambiguous parasites were
visualized and clearly identified after examining about
0.55 μL of blood in a Giemsa-stained thick smear.
Table 5 summarizes the results for all assays evaluated
and illustrates the day of detection for each clinical
sample by each qPCR assay (first Cq value obtained) as
compared to microscopy. The performance of each qPCR
assay was assessed by comparing the number of days each
assay detected parasites before microscopy. The PLU3
assay was the most sensitive, detecting parasites on
average three days before microscopy, whereas the FAL
assay was the least sensitive, detecting parasite only
0.6 days before microscopy.
Discussion
A variety of diagnostic methods exist that are used for
identification and speciation of Plasmodium parasites.
Microscopic detection of malaria parasites on Giemsa-
stained blood smears is still considered the gold standard
method for malaria diagnosis, clinical trials efficacy evalu-
ation and epidemiological surveys. However, microscopy
has numerous limitations such as low sensitivity, diffi-
culties in quality control and standardization, operator
dependence, poor specificity, and the need for con-
tinued training and evaluation [4,6,23,24]. Identifica-
tion of parasites specific antigens, antibodies and nucleic
acid sequences form the basis of established and novel diag-
nostic modalities. Nucleic acid amplification technique-
based assays, such as qPCR are becoming increasingly
employed in the diagnosis of malaria [12,15,25,26]. Studies
Table 5 Clinical trial study




































Table 5 Clinical trial study (Continued)





Table showing the number of Days (D) the samples became positive (P) by
either microscopy (Micro) or qPCR assays. D1 is the day when the first qPCR
assay was positive. The designation of days is arbitrary for comparison of qPCR
assays to microscopy and does not reflect the actual day of qPCR positivity
post infection challenge. DBM is the number of days samples were qPCR
positive before they became microscopy positive. The actual Cq values are not
shown. The last column shows the average number of days (Avg DBM) the
samples were qPCR positive (for each assay) before they were microscopy
positive for all the five volunteers.
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proved sensitivity and species identification compared
to microscopy [7,14]. There is a wide variation in the
sensitivity of the numerous PCR methods that have
been developed for the laboratory diagnosis and clinical
management of malaria [21]. These differences may be
attributed to the intrinsic variability in assay sensitivity
or a consequence of calibration using different reference
reagents, which are poorly standardized [12]. In this study,
the WHO International Standard for P. falciparum DNA
was used as a calibration reference reagent to compare the
sensitivity of a few published qPCR assays for detection
of malaria. The MIQE guidelines were followed during
experiment set-up and execution to ensure relevance,
accuracy, correct interpretation, and repeatability of the
assays that were being analysed and compared. The PLU3
assay performed extremely well and was consistent com-
pared to the other assays regardless of the assay format
(either TaqMan probe or SYBR green) or background
(QuantiFast probe Master Mix, QuantiFast SYBR green
Master Mix or QuantiTect SYBR green Master Mix).
The MACH assay performed equally well. There is
probably other qPCR malaria assays not included, pub-
lished or not, that might perform as well or better. With
exception of the WHO assay, all the qPCR assays tested
had higher LoD (less sensitive) compared to the pub-
lished LoD. This difference can be explained by many
factors including calibration using different reference
reagents and data interpretation.
Although sensitivity is important, other factors should
be considered when designing or selecting qPCR assay
to adopt or use in a project. Plasmodium falciparum
growth is usually characterized by an exponential increase
in the number of parasite-infected erythrocytes, followed
by marked oscillations in this number with a periodicity
of 48 hours, which are eventually dampened [27]. This
reproductive pattern leads to variation in parasite dens-
ities in peripheral blood. As such, the small differences
in assay sensitivity demonstrated here might not be
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require qPCR assays with different sensitivities. The se-
verity of malaria disease does not just depend on the
parasite density, but depends on many factors such the
immune status of the patient or subject in addition
to other factors. For non-immune patients or subjects,
smaller amounts (or changes thereof) of parasites may
cause malaria disease much more compared to immune
patients or subjects, therefore requiring qPCR with higher
sensitivity. However, regardless of the setting, qPCR assays
must be consistent and reproducible in addition to being
highly sensitive; these qualities can be established if
qPCR assays are designed and tested following the
MIQE guidelines.
Some of the key characteristics that are critical in
qPCR experiments and must be considered conceptually
include analytical sensitivity, analytical specificity, accur-
acy, repeatability, and reproducibility. It is important
that published assays are reproducible within reason or
range if performed following the same chemistries and
platform as those described in respective publication.
Even with change in chemistries and platform, the per-
formance of the assay should remain relatively consistent.
Such characteristic (consistency) in performance can only
be evaluated if the assay calibration is done using a stand-
ard reference reagent, such as the WHO International
Standard for P. falciparum DNA. The quality and integ-
rity of the nucleic acids being analysed is just as critical
in performance of the assay. Therefore, use of standard
controls, such as the WHO International Standard for
P. falciparum DNA, in every qPCR assay as positive
control is critical in ensuring that the qPCR assays per-
form consistently. To ensure consistency and minimize
variability, all the assays tested here were performed on
the same 96-well plate when possible and the same
DNA dilutions were used in all the assays.
Data analysis is also important in ensuring impartial
results. In most qPCR platforms, the post-run data are
analysed using the software supplied with the instru-
ment. Proper baseline and threshold setting is required
in getting a final quantifiable Cq value for each run. Such
settings can be done manually or automatically in open
qPCR platforms. Manually changing the threshold set-
tings can drastically change the Cq values. It is likely that
such practices account for dramatic differences seen in
obtained and published LoD. To ensure that there was
no bias towards data interpretation and analysis in this
study, automatic manufacturer’s settings were used to
establish threshold and for data interpretation.
The performance of the assays in analysis of the clin-
ical trial samples corresponded well with the established
base-line performance of the assays. The PLU3 assay
which had been established to be the most sensitive,
detected parasites on average three days before microscopyfollowed by the MACH assay. The FAL assay was the least
sensitive; had the lowest performance in the analysis of
clinical samples and had the worst LoD. These data show
that proper evaluation of molecular assays following
proper guidelines results in an assay with reliable, re-
producible and superior performance.Conclusion
For the first time, the performances of several PCR as-
says developed by different laboratories for detection of
malaria have been compared side by side. To ensure un-
biased and objective comparison of the performance of
the qPCR assays, data was generated with clearly de-
fined experimental design, procedures and instrumenta-
tion for DNA extraction, as well as the analysis. In
addition, qPCR assays tested were validated using MIQE
guidelines and commercially available reference DNA
sample. When designing and evaluating qPCR assays,
the focus should be the chemistries regardless of the
background and platform used. Data presented here
show that qPCR assays with superior performance
characteristics such as high efficiency and precision per-
form better in analysis of clinical samples than those
with poor performance characteristics. With exception
of the WHO assay, qPCR assays analysed did not per-
form with similar sensitivities as previously shown. It
is recommended that the work described here, either
using the same and/or additional malaria qPCR assays
be performed by other group(s) as well. It is absolutely
important that such testing and comparison of the perfor-
mances of qPCR assays use well defined guidelines such
as MIQE and same reference reagent(s) such as the WHO
International Standard for P. falciparum DNA. Reference
reagent(s) can also be prepared internally but the same
reagent(s) must be shared and used by all the participa-
ting laboratories in such a study.
The purpose of this study was not to endorse or discredit
any of the published assays. It is likely most established
laboratories will continue using their laboratory devel-
oped qPCR assays for detection of malaria. However, it
is critical to reach a consensus or standardized method
of performing qPCR assay to facilitate the evaluation
and/or comparison of the qPCR assays reported by diffe-
rent authors and laboratories. This will be especially impor-
tant for a cross-study and/or cross-platform comparison.
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